OncoMatch/Clinical Trials/NCT04100174

Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy

Is NCT04100174 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for prostate cancer.

Phase 2RecruitingCentre hospitalier de l'Université de Montréal (CHUM)NCT04100174Data as of May 2026

To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify